A U.S. Perspective on Global Strategy
March-in Rights and Compulsory Licensing of Biopharmaceutical Inventions
Very few topics in international intellectual property have been as controversial as compulsory licensing. In the US, consumer groups have increasingly focused on march-in rights as a mechanism to lower drug costs. The October 2017 issue of Sterne Kessler’s Global Patent Prosecution Newsletter includes information on march-in rights in the US and the use of compulsory licenses worldwide.
In this issue: